Keyword: Johnson & Johnson
Patent litigation and long-dated payer contracts are among the “unacceptable” tactics Gottlieb criticized for stalling biosim competition.
Amid an industrywide debate over drug prices, top player J&J reports its net prices will fall between 4% and 6% in 2018.
J&J’s Invokana will have to wait longer for the FDA to decide on a key label expansion, but it's still got good news to celebrate.
Pfizer and Astellas’ prostate cancer med Xtandi nabbed broader FDA approval, setting it up for a head-to-head fight with J&J’s Erleada.
Johnson & Johnson has suffered its largest talc defeat to date, and the damages came in significantly above previous verdicts.
Biogen and Eisai's anti-amyloid candidate shows promise; Otsuka signs two M&A deals; Samsung BioLogics faces criminal probe over Biogen JV agreement.
With Johnson & Johnson's diabetes drug Invokana going up against two longtime rivals in China, the company is ramping things up.
J&J and AbbVie’s Imbruvica hasn’t run into many stumbling blocks. But it has hit one in non-Hodgkin lymphoma.
Johnson & Johnson immunology newcomer Tremfya is looking to follow in the footsteps of its big brother Stelara.
Here is some other vaccine news of note for the week.